2h6o
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==Epstein Barr Virus Major Envelope Glycoprotein== | ==Epstein Barr Virus Major Envelope Glycoprotein== | ||
- | <StructureSection load='2h6o' size='340' side='right'caption='[[2h6o]] | + | <StructureSection load='2h6o' size='340' side='right'caption='[[2h6o]]' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'> | + | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2H6O OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2H6O FirstGlance]. <br> |
- | </td></tr> | + | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2h6o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2h6o OCA], [https://pdbe.org/2h6o PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2h6o RCSB], [https://www.ebi.ac.uk/pdbsum/2h6o PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2h6o ProSAT]</span></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
</table> | </table> | ||
- | <div style="background-color:#fffaf0;"> | ||
- | == Publication Abstract from PubMed == | ||
- | Epstein-Barr virus (EBV) infection of B cells is associated with lymphoma and other human cancers. EBV infection is initiated by the binding of the viral envelope glycoprotein (gp350) to the cell surface receptor CR2. We determined the X-ray structure of the highly glycosylated gp350 and defined the CR2 binding site on gp350. Polyglycans shield all but one surface of the gp350 polypeptide, and we demonstrate that this glycan-free surface is the receptor-binding site. Deglycosylated gp350 bound CR2 similarly to the glycosylated form, suggesting that glycosylation is not important for receptor binding. Structure-guided mutagenesis of the glycan-free surface disrupted receptor binding as well as binding by a gp350 monoclonal antibody, a known inhibitor of virus-receptor interactions. These results provide structural information for developing drugs and vaccines to prevent infection by EBV and related viruses. | ||
- | |||
- | Structure of the Epstein-Barr virus major envelope glycoprotein.,Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, Holers VM, Chen XS Nat Struct Mol Biol. 2006 Nov;13(11):996-1001. Epub 2006 Oct 29. PMID:17072314<ref>PMID:17072314</ref> | ||
- | |||
- | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
- | </div> | ||
- | <div class="pdbe-citations 2h6o" style="background-color:#fffaf0;"></div> | ||
- | == References == | ||
- | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: Ebvg]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
- | [[Category: Chen | + | [[Category: Chen XS]] |
- | + | ||
- | + |
Revision as of 10:02, 12 May 2021
Epstein Barr Virus Major Envelope Glycoprotein
|